A large study reveals an increased risk for adverse cardiovascular events but not for liver disease progression in adults with MASLD disease and HIV infection.
New restrictions have been imposed by the European Medicines Agency on the coadministration of the anti-HIV drug atazanavir with a variety of other agents.